Surgical Sperm Retrieval — Cost, Top Hospitals & Success Rates | MyMedicPlus

Surgical sperm retrieval (SSR) is a group of minimally invasive urological procedures designed to extract viable sperm directly from the male reproductive tract — either from the epididymis or the testis — when sperm are absent from the ejaculate. This condition, known as azoospermia, affects approximately 1% of all men and accounts for 10–15% of male infertility cases. Azoospermia may be obstructive (OA) — where sperm production is normal but the delivery pathway is blocked — or non-obstructive (NOA), where the testes themselves produce little or no sperm due to an underlying spermatogenic failure.

The development of intracytoplasmic sperm injection (ICSI) in 1992 was a landmark advance that transformed SSR from a procedure of limited utility into a cornerstone of male infertility treatment. ICSI requires only a single viable spermatozoon per egg, meaning that even very small quantities of surgically retrieved sperm can be used to fertilise oocytes and achieve pregnancy. SSR + ICSI has enabled biological fatherhood for men who would previously have had no chance of conception with their own genetic material.

The main SSR techniques include: Percutaneous Epididymal Sperm Aspiration (PESA), Microsurgical Epididymal Sperm Aspiration (MESA), Testicular Sperm Aspiration (TESA), Testicular Sperm Extraction (TESE), and Microsurgical TESE (Micro-TESE). The choice of technique depends on the aetiology of azoospermia, the volume of sperm expected, the infrastructure available, and the preference and expertise of the surgical team and reproductive laboratory.

SSR is not a standalone fertility treatment — it must be coordinated with a female partner's controlled ovarian stimulation and egg retrieval cycle, typically as part of an in vitro fertilisation (IVF) program. Careful synchronisation, cryopreservation planning, and multidisciplinary team coordination between the andrologist, reproductive endocrinologist, and embryologist are all critical to success.

Surgical sperm retrieval is indicated for a range of conditions that result in azoospermia or severely reduced ejaculated sperm that is insufficient for natural conception or standard IVF. Precise diagnosis of the underlying cause guides the choice of SSR technique and sets realistic expectations for sperm recovery rates.

Obstructive Azoospermia (OA)

In obstructive azoospermia, sperm production in the testes is normal (FSH and testicular volume are typically normal), but a blockage somewhere in the reproductive tract prevents sperm from reaching the ejaculate. Obstructive causes include:

• Congenital bilateral absence of the vas deferens (CBAVD): The most common cause of OA, affecting approximately 1–2% of infertile men. Almost always associated with CFTR gene mutations (cystic fibrosis gene). Sperm are present in abundance in the epididymis, making PESA or MESA highly successful.
• Previous vasectomy: Intentional bilateral vas deferens occlusion. SSR is an alternative to vasectomy reversal, particularly when reversal has failed or when the couple prefers to combine SSR with IVF.
• Post-infective obstruction: Scarring of the epididymis or vas deferens following sexually transmitted infections (gonorrhoea, chlamydia) or epididymo-orchitis.
• Ejaculatory duct obstruction (EDO): Blockage of the ejaculatory ducts by cysts, calcification, or inflammation, causing low-volume azoospermia. May be treated by transurethral resection of ejaculatory ducts (TURED) or managed with SSR.
• Failed vasectomy reversal: Secondary obstruction or failed anastomosis after prior vasovasostomy or vasoepididymostomy.

Non-Obstructive Azoospermia (NOA)

NOA reflects a primary failure of spermatogenesis. Sperm may still be present in small focal pockets within the testes. Causes include:

• Klinefelter syndrome (47,XXY): The most common genetic cause of NOA, affecting 1 in 600 males. Micro-TESE achieves sperm retrieval in 40–60% of cases.
• Y-chromosome microdeletions: Deletions in the AZFc region allow sperm retrieval; AZFa and AZFb deletions are associated with complete spermatogenic failure and very low retrieval rates.
• Idiopathic spermatogenic failure: No identifiable cause. Micro-TESE retrieval rate 30–50%.
• Post-chemotherapy or radiation azoospermia: Gonadotoxic treatments may cause temporary or permanent spermatogenic failure.
• Hypogonadotropic hypogonadism: Low FSH/LH causes; often amenable to hormonal stimulation before SSR.

Eligibility for surgical sperm retrieval is determined by a comprehensive andrological evaluation. Not all men with azoospermia are equally good candidates, and differentiating obstructive from non-obstructive azoospermia is crucial before recommending a specific SSR technique.

Diagnostic Workup Before SSR

• Semen analysis (x2): Two semen analyses confirming azoospermia (no sperm on standard microscopy or after centrifugation).
• Hormonal profile: Serum FSH, LH, testosterone, prolactin, and inhibin B. Elevated FSH with low inhibin B strongly suggests NOA. Normal FSH with palpable testicular volume suggests OA.
• Testicular ultrasound: Identifies testicular size, varicoceles, microlithiasis, or masses. Epididymal fullness is seen in OA.
• Genetic testing: Karyotype (to detect Klinefelter syndrome) and Y-chromosome microdeletion analysis are mandatory in NOA. CFTR mutation testing is required before CBAVD SSR to counsel about cystic fibrosis risk in offspring.
• Diagnostic testicular biopsy: May be performed to confirm spermatogenic status if hormonal and imaging data are inconclusive.

Eligibility Criteria

• Confirmed azoospermia on two separate semen analyses.
• Female partner has completed fertility assessment and is suitable for IVF/ICSI.
• Both partners have received genetic and reproductive counselling regarding the SSR technique, expected success rates, and risks to offspring (e.g., transmission of CFTR mutations, Y-chromosome deletions).
• The male partner has no active genital tract infection (treat and resolve before SSR).
• Age: SSR can be performed at any adult age, though sperm quality and retrieval rates decline with advancing age, particularly in NOA patients.
• Post-chemotherapy patients should ideally wait 12–24 months after completion of treatment before SSR to allow partial spermatogenic recovery.

Five main surgical techniques are used, each with specific indications, advantages, and limitations. The choice is guided by the type of azoospermia, anticipated sperm availability, and the laboratory's cryopreservation capability.

PESA — Percutaneous Epididymal Sperm Aspiration

PESA is the simplest and least invasive SSR technique. A fine needle is inserted percutaneously (through the scrotal skin) into the epididymis under local anaesthesia and sperm-containing fluid is aspirated. Performed in an outpatient setting in 15–30 minutes. PESA is ideal for obstructive azoospermia (CBAVD, post-vasectomy), where sperm are plentiful in the dilated epididymis. Sperm retrieval rates: 80–95% in OA. Limitation: blind aspiration may yield lower sperm numbers and more blood contamination than MESA.

MESA — Microsurgical Epididymal Sperm Aspiration

MESA is performed under the operating microscope with the scrotum open, allowing direct visualisation of individual epididymal tubules. A selected tubule is incised and fluid is aspirated. MESA consistently yields the highest sperm counts and quality of all epididymal techniques, providing enough sperm for multiple ICSI cycles and cryopreservation. It is the gold standard for CBAVD and is preferred when multiple cycles or embryo banking are planned. Performed under general or spinal anaesthesia. Recovery 1–3 days.

TESA — Testicular Sperm Aspiration

TESA uses a needle passed directly into the testicular parenchyma to aspirate testicular tissue and sperm. A simpler approach than TESE, it can be performed under local anaesthesia in an outpatient setting. Suitable for OA where epididymal SSR has failed and for selected NOA cases. Sperm retrieval in OA: 85–95%. In NOA: 30–50%. Yields fewer sperm than TESE and is less suitable for cryopreservation banking.

TESE — Testicular Sperm Extraction (Conventional)

TESE involves making one or more small incisions in the testis and removing small pieces of testicular tissue under direct vision, which are then processed in the embryology laboratory to find sperm. Performed under general or sedation anaesthesia. Conventional TESE achieves sperm retrieval in 40–60% of NOA cases. Limitation: random biopsy sampling may miss focal spermatogenesis, and repeated conventional TESE can cause testicular damage reducing future testosterone production.

Micro-TESE — Microsurgical Testicular Sperm Extraction

Micro-TESE is the most technically demanding and most effective technique for NOA. The testis is opened and examined under high magnification (16–25x operating microscope). Surgeons identify dilated seminiferous tubules that are more likely to contain sperm (enlarged tubules correlate with active spermatogenesis). Targeted biopsies are taken only from these tubules. Micro-TESE retrieval rates in NOA: 40–60% overall, with rates up to 70% in Klinefelter syndrome. It causes less testicular tissue removal than conventional TESE and is associated with better preservation of testicular function. Considered the gold standard for NOA.

Surgical sperm retrieval has transformed the treatment landscape for men with azoospermia, enabling biological fatherhood in many cases that were previously considered untreatable.

• Enables biological parenthood: SSR combined with ICSI allows men with azoospermia to father biological children. Without SSR, their only options would be donor sperm or adoption. This is the primary and most profound benefit.
• High success rates in obstructive azoospermia: PESA and MESA achieve sperm retrieval in 85–95% of OA cases. ICSI fertilisation rates with retrieved sperm are 60–75%, with clinical pregnancy rates per cycle of 40–55% in younger women — comparable to conventional IVF outcomes.
• Viable option for non-obstructive azoospermia: Micro-TESE offers men with NOA — previously considered completely infertile — a 40–60% chance of sperm retrieval. Even men with Klinefelter syndrome, AZFc deletions, and idiopathic NOA may successfully father children through Micro-TESE + ICSI.
• Sperm cryopreservation: Retrieved sperm can be frozen (cryopreserved) for use in multiple future ICSI cycles, reducing the need for repeated SSR procedures. MESA is particularly well-suited to banking as it typically yields large numbers of sperm.
• Minimally invasive options: PESA and TESA can be performed as outpatient procedures under local anaesthesia, with minimal pain, no hospitalisation, and return to normal activity within 24–48 hours.
• Complementary to vasectomy reversal: SSR provides an alternative when vasectomy reversal has failed or when the couple does not wish to wait for natural conception to establish after reversal.
• Simultaneous diagnostic and therapeutic benefit: SSR provides definitive diagnosis of spermatogenic status (testicular vs. obstructive) while simultaneously retrieving sperm for immediate use or cryopreservation.

Surgical sperm retrieval is generally safe, especially when performed by experienced reproductive urologists. However, as with any surgical procedure, complications can occur and patients should be fully informed before consenting.

Risks Common to All SSR Techniques

• Failure to retrieve sperm: The most significant risk, particularly in NOA. Even Micro-TESE fails in 40–60% of NOA cases. This is devastating for couples who have undergone a simultaneous IVF stimulation cycle for the female partner. Risk mitigation includes pre-operative hormone profiling, genetic testing, and diagnostic testicular biopsy before committing to a full IVF cycle.
• Haematoma: Bleeding into the scrotum, causing swelling, bruising, and pain. Small haematomas resolve spontaneously; large haematomas may require surgical evacuation (rare, <1%).
• Infection: Epididymo-orchitis or scrotal abscess. Uncommon (<1–2%) with appropriate sterile technique and post-operative antibiotic prophylaxis.
• Pain: Mild to moderate scrotal discomfort is expected for 1–5 days post-procedure. Managed with NSAIDs (ibuprofen) and scrotal support.

Technique-Specific Risks

• PESA: Fibrosis of epididymal tubules from repeated aspirations, making subsequent PESA or MESA attempts more difficult. Repeated needle punctures may cause inflammation.
• TESE/Micro-TESE: Reduction in testicular testosterone production post-procedure. Conventional TESE (multiple random biopsies) causes more tissue removal and has a greater risk of long-term hypogonadism than Micro-TESE. Studies report testosterone reduction in up to 20% of patients after conventional TESE vs. 5–10% with Micro-TESE.
• Hydrocele: Collection of fluid around the testis after open scrotal surgery, occasionally requiring aspiration.
• Testicular atrophy: A rare but serious complication of extensive testicular surgery, particularly with vascular compromise. Micro-TESE's magnified approach minimises this risk by preserving testicular vasculature.

Genetic Risks to Offspring

• Children conceived through SSR from men with Y-chromosome microdeletions (AZFc) will inherit the deletion and are likely to be infertile, requiring SSR themselves.
• Children of CBAVD fathers conceived with SSR carry at least one CFTR mutation and, if the female partner also carries a mutation, have a 25–50% risk of cystic fibrosis. Pre-implantation genetic testing (PGT) and prenatal diagnosis should be discussed.

Recovery from SSR is generally quick, though the overall journey to parenthood continues with the IVF/ICSI cycle. Follow-up care encompasses both the immediate post-operative period and the subsequent reproductive treatment steps.

Immediate Post-Operative Care (0–48 Hours)

• Patients are discharged the same day (PESA, TESA) or after a brief observation period (MESA, TESE). General anaesthesia patients are monitored until fully recovered before discharge.
• A fitted scrotal support (jockstrap or athletic supporter) should be worn continuously for 48–72 hours to reduce swelling and support healing.
• Ice packs wrapped in a cloth applied to the scrotum for 15–20 minutes every few hours in the first 24 hours help control oedema.
• Pain is managed with paracetamol (1 g, 4-hourly as needed) and ibuprofen 400 mg three times daily with food. Strong opioid analgesics are rarely required.
• Rest on the day of procedure. Light activities resume the following day; strenuous physical activity, heavy lifting, and sexual activity should be avoided for 5–7 days.

First Two Weeks

• Follow-up with the andrologist at 1–2 weeks to assess wound healing, rule out infection or haematoma, and discuss sperm retrieval results and cryopreservation outcome.
• Men who had TESE or Micro-TESE should have scrotal ultrasound at 4–6 weeks if significant post-operative swelling or discomfort persists.
• If sperm were successfully cryopreserved, the reproductive team will advise on the IVF/ICSI protocol and timeline for the female partner's stimulation cycle.

Ongoing Reproductive Follow-Up

• Hormonal monitoring (testosterone, FSH, LH) at 3 and 6 months post-Micro-TESE or TESE to detect procedure-related hypogonadism. Testosterone supplementation may be required if levels drop significantly.
• If SSR fails (no sperm retrieved), a multidisciplinary team review should reassess the diagnosis and consider: repeat SSR after 6–12 months of hormonal stimulation (FSH or clomiphene), participation in clinical trials, or counselling about donor sperm and alternative family-building options.
• Psychological support: couples undergoing SSR for infertility face significant emotional stress. Access to a fertility counsellor experienced in male infertility is strongly recommended throughout the treatment journey.

The cost of surgical sperm retrieval is typically quoted as part of a comprehensive IVF/ICSI package, though SSR may also be performed as a standalone diagnostic or sperm-banking procedure. Costs vary widely by technique, country, and whether fresh or frozen sperm use is planned.

SSR Technique Costs

• PESA: USD 500–2,000 in the USA. USD 200–600 in India, Turkey, or Thailand. The simplest and least costly technique.
• TESA: USD 800–2,500 in the USA. USD 300–800 in South/Southeast Asia. Often combined with ICSI cycle cost.
• MESA: USD 3,000–8,000 in the USA and Western Europe (requires operating microscope and experienced microsurgeon). USD 1,000–3,000 in India at high-volume fertility centres.
• TESE (Conventional): USD 2,500–6,000 in the USA. USD 800–2,500 in India or Southeast Asia.
• Micro-TESE: USD 5,000–12,000 in the USA (specialist microsurgical centre required). USD 1,500–4,000 in India at institutions like Manipal, Apollo, or AIIMS. Costs reflect the extended surgical time, operating microscope use, and specialist andrologist/reproductive urologist fees.

IVF/ICSI Cycle Costs (Required Alongside SSR)

• USA: USD 12,000–20,000 per cycle (excluding SSR and medications). Total treatment including Micro-TESE + ICSI: USD 20,000–35,000.
• India: USD 2,500–5,000 per IVF/ICSI cycle. Total treatment with SSR: USD 4,000–9,000.
• Spain / Czech Republic / Greece (popular European fertility destinations): EUR 4,000–7,000 per IVF/ICSI cycle.

Additional Cost Factors

• Sperm cryopreservation and annual storage fees (USD 300–600/year)
• Pre-genetic testing of embryos (PGT-A or PGT-M) if chromosomal or monogenic disorders are a concern: USD 3,000–6,000 additional
• Pre-operative diagnostic workup: hormonal tests, karyotype, Y-microdeletion panel, CFTR testing
• Female partner's ovarian stimulation medications (USD 3,000–6,000 in the USA; lower in countries with negotiated generic drug prices)
• Number of IVF cycles anticipated (costs multiplied if multiple cycles are needed)

SSR is generally not covered by most health insurance plans globally, though some countries (Israel, several European nations) include IVF and SSR within public health coverage for eligible couples. Patients should confirm coverage before commencing treatment.

Depending on the underlying cause of azoospermia, medical or surgical alternatives to SSR may restore natural sperm production or improve the ejaculate sufficiently to avoid needle-based retrieval. In other situations, donor sperm or adoption may be the only remaining options if SSR is not successful.

Medical Management Before SSR

• Hormonal stimulation (for hypogonadotropic hypogonadism): Men with azoospermia caused by low FSH/LH (secondary hypogonadism) can achieve spermatogenesis with gonadotropin injections (FSH + hCG) or pulsatile GnRH therapy. Sperm may appear in the ejaculate after 3–12 months, potentially avoiding SSR. Success rates: 70–90% for sperm recovery in ejaculate.
• Hormonal stimulation before Micro-TESE (for NOA): Treatment with clomiphene citrate, anastrozole, or FSH injections for 3–6 months before Micro-TESE may improve spermatogenic foci and increase retrieval rates in NOA patients, particularly those with AZFc deletions or prior hypogonadism. This is increasingly used as a Micro-TESE priming strategy.
• Varicocele repair: A varicocele (dilated veins around the testis) is present in 35–40% of infertile men and can suppress spermatogenesis. Surgical varicocelectomy (microsurgical subinguinal varicocelectomy) may restore sperm to the ejaculate in 30–50% of men with NOA plus palpable varicocele, potentially avoiding SSR.

Vasectomy Reversal (Vasovasostomy / Vasoepididymostomy)

For post-vasectomy azoospermia, vasectomy reversal offers the chance of natural conception without IVF. Patency rates are high (90–95% for vasovasostomy within 5 years of vasectomy) but decline with increasing time from vasectomy. Pregnancy rates depend on female partner age and sperm quality. For couples where the female partner is older or where IVF is already planned, SSR + ICSI is often preferred as it is faster and more predictable in outcome.

Transurethral Resection of Ejaculatory Ducts (TURED)

For ejaculatory duct obstruction, TURED is a minimally invasive endoscopic procedure that may restore ejaculated sperm to the semen, avoiding need for SSR. Success (sperm in ejaculate post-TURED) is achieved in 50–65% of selected cases.

Donor Sperm

For couples where SSR has failed repeatedly or is not technically feasible, donor sperm insemination (IUI with donor sperm) or donor sperm IVF/ICSI provides a very high pregnancy success rate and avoids the physical and emotional burden of repeated SSR procedures. Psychological counselling is recommended before this path is chosen.